HomePublications

Publications & research.

Scientific publications and research outputs associated with PNB Vesper's development programmes.

16 publications, 15 with a file to download.

Clinical research

Human trial reports for PNB-001, the lead molecule.

  1. Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB-001 in Moderate COVID-19 Patients

    Source
    medRxiv
    Year
    2021
    Type
    Preprint
    Molecule
    PNB-001
    Indication
    COVID-19
    Trial summary
    Phase 2, COVID-19

    Randomized, comparative clinical trial evaluating the efficacy and safety of PNB-001 in moderate COVID-19 patients.

  2. A Randomized, Comparative Clinical Trial to Evaluate Efficacy and Safety of PNB-001 as Immune Modulator in Moderate COVID-19 Patients

    Source
    Medwin Publishers
    Type
    Journal article
    Molecule
    PNB-001
    Indication
    COVID-19
    Trial summary
    Phase 2, COVID-19

    Randomized, comparative clinical trial evaluating PNB-001 as an immune modulator in moderate COVID-19 patients.

  3. A Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB-001 as Immune Modulator in Moderate COVID-19 Patients

    Source
    ResearchGate
    Type
    Document
    Molecule
    PNB-001
    Indication
    COVID-19
    Trial summary
    Phase 2, COVID-19

    The document shared on ResearchGate for the same PNB-001 trial in moderate COVID-19.

Oncology

Preclinical studies of CCK receptor antagonists in colon, pancreatic, lung and Brain Cancer.

  1. Novel, isoform-selective, cholecystokinin A receptor antagonist inhibits colon and pancreatic cancers in preclinical models through novel mechanism of action

    Source
    Oncology Reports
    Year
    2016
    Type
    Journal article
    Molecule
    PNB-028
    Indication
    Colon and Pancreatic Cancer
    Read the abstract
  2. Cholecystokinin-1 receptor antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anticancer agents

    Source
    MedChemComm
    Year
    2016
    Type
    Journal article
    Molecule
    PNB-028
    Indication
    Colon and Pancreatic Cancer
    Read the abstract
  3. Irreversible Cholecystokinin-1 Receptor Antagonists PNB-028/81: N-Isobutyl-5-Hydroxy-5-Aryl-Pyrrol-2-Ones as Experimental Therapeutic Agents against Colon and Pancreatic Cancer

    Type
    Journal article
    Molecules
    PNB-028, PNB-081
    Indication
    Colon and Pancreatic Cancer
  4. Irreversible Cholecystokinin-1 Receptor Antagonists PNB-028/81: N-Isobutyl-5-Hydroxy-5-Aryl-Pyrrol-2-Ones as Experimental Therapeutic Agents against Colon and Pancreatic Cancer

    Type
    Journal article
    Molecules
    PNB-028, PNB-081
    Indication
    Colon and Pancreatic Cancer

    Listed as a second entry under the same title, with its own file, on the previous website.

  5. N-substituted 5-hydroxy-pyrrol-2-ones based cholecystokinin-2 antagonists as experimental anticancer agents for the treatment of Lung Cancer

    Source
    MOJ Drug Design Development & Therapy
    Year
    2018
    Type
    Journal article
    Molecule
    PNB-101
    Indication
    Lung Cancer
  6. Cholecystokinin Antagonists: Fluorinated 5-Hydroxy-5-Aryl-Pyrrol-2-Ones as Experimental Agents for Brain, Colon and Pancreatic Cancer

    Source
    MedCrave
    Type
    Journal article
    Subject
    Brain, colon and Pancreatic Cancer

Inflammation & pain

CCK-2/gastrin antagonists as anti-inflammatory analgesics, and as an adjunct to opiates.

  1. Cholecystokinin-2/gastrin antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anti-inflammatory analgesics for the treatment of Inflammatory Bowel Disease

    Source
    MedChemComm
    Year
    2017
    Type
    Journal article
    Molecule
    PNB-001
    Indication
    Inflammatory Bowel Disease

    No file was attached to this entry on the previous website; the article is available from the publisher.

  2. CCK2 Gastrin Antagonist: Development of PNB-001 (4-Chloro-5-Hydroxy-1-Phenylethyl-5-Phenyl-1,5-Dihydro-Pyrrol-2-One) as Anti-Inflammatory Analgesic

    Type
    Journal article
    Molecule
    PNB-001
    Indication
    Inflammation and pain
  3. From Merck’s CCK-Antagonists via 4-Amino-2(5H)-Furanones towards 5-Hydroxy-Pyrrol-2-Ones: Design, Synthesis and Evaluation of PNB-001 & PNB-081 as Experimental Therapeutic Agents in Pain Management

    Source
    Drug Designing & Intellectual Properties International Journal
    Type
    Journal article
    Molecules
    PNB-001, PNB-081
    Indication
    Pain Management
  4. CCK-Antagonist PNB-081 (Isobutyl-5-Hydroxy-5-Phenyl-Pyrrol-2-One) as Adjunct to Opiates

    Type
    Journal article
    Molecule
    PNB-081
    Indication
    Opiate Management
  5. Analgesic Effects of 5-Alkyloxy-4-amino-2(5H)-furanones as Cholecystokinin-2 Antagonists

    Source
    Archiv der Pharmazie
    Year
    2016
    Type
    Journal article
    Subject
    Pain

Discovery & preclinical

Where the chemistry started, and the preclinical work that led to the first human trial.

  1. Breaking into Merck’s CCK Patents: the Starting Point of PNB Vesper Life Science to Design and Develop Cholecystokinin (CCK)-Antagonists as Targeted Chemotherapeutics

    Source
    Drug Designing & Intellectual Properties International Journal
    Type
    Journal article
    Subject
    CCK antagonist design
  2. Pre-Clinical Evaluation of CCK2 Antagonist PNB-001 (4-Chloro-5-Hydroxy-1-Phenylethyl-5-Phenyl-1,5-Dihydro-Pyrrol-2-One) Towards the Design for a First-in-Man Clinical Trial

    Type
    Journal article
    Molecule
    PNB-001
    Indication
    First-in-human trial design

Selected abstracts.

Two peer-reviewed papers on CCK-A (CCK-1) receptor antagonists in colon and Pancreatic Cancer, as published in international journals.

[4] Oncology Reports 35: 2097–2106, 2016

Novel, isoform-selective, cholecystokinin A receptor antagonist inhibits colon and pancreatic cancers in preclinical models through novel mechanism of action

PNB-028 Colon and Pancreatic Cancer

Download the full paperPDF: Novel, isoform-selective, cholecystokinin A receptor antagonist inhibits colon and pancreatic cancers in preclinical models through novel mechanism of action (opens in a new tab)

Colon and pancreatic cancers contribute to 90,000 deaths each year in the USA. These cancers lack targeted therapeutics due to heterogeneity of the disease and multiple causative factors. One important factor that contributes to increased colon and Pancreatic Cancer risk is gastrin. Gastrin mediates its actions through two G-protein coupled receptors (GPCRs): cholecystokinin receptor A (CCK-A) and CCK-B/gastrin receptor. Previous studies have indicated that Colon Cancer predominantly expresses CCK-A and responds to CCK-A isoform antagonists. However, many CCK-A antagonists have failed in the clinic due to poor pharmacokinetic properties or lack of efficacy. In the present study, we synthesized a library of CCK-A isoform-selective antagonists and tested them in various colon and Pancreatic Cancer preclinical models. The lead CCK-A isoform, selective antagonist PNB-028, bound to CCK-A at 12 nM with a 60-fold selectivity towards CCK-A over CCK-B. Furthermore, it inhibited the proliferation of CCK-A-expressing colon and Pancreatic Cancer cells without affecting the proliferation of non-cancerous cells. PNB-028 was also extremely effective in inhibiting the growth of MAC-16 and LoVo Colon Cancer and MIA PaCa Pancreatic Cancer xenografts in immune-compromised mice. Genome-wide microarray and kinase-array studies indicate that PNB-028 inhibited oncogenic kinases and angiogenic factors to inhibit the growth of Colon Cancer xenografts. Safety pharmacology and toxicology studies have indicated that PNB-028 is extremely safe and has a wide safety margin. These studies suggest that targeting CCK-A selectively renders promise to treat colon and pancreatic cancers and that PNB-028 could become the next-generation treatment option.

[5] MedChemComm, United Kingdom, 2016

Cholecystokinin-1 receptor antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anticancer agents

PNB-028 Colon and Pancreatic Cancer

Download the full paperPDF: Cholecystokinin-1 receptor antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anticancer agents (opens in a new tab)

A new class of 5-arylated 5-hydroxypyrrolones was derived from mucochloric acid in 2 synthetic steps and the chemical structure was confirmed additionally by x-ray analysis. Using a radiolabelled binding assay, potent CCK1 selective ligands were identified (CCK1: 12 nM) and the antagonism was confirmed by using isolated tissue preparations. A series of isobutyl derivatives displayed unsurmountable CCK antagonistic properties and in vitro excellent inhibition of proliferation was obtained in cholecystokinin related cancer cell lines in the nanomolar range. Finally, using xenograft studies in nude mice, two selected pyrrolone derivatives, X=H and X=F, a fluorinated analogue (PNB-028), showed a strong inhibition of tumour growth in a chemo-resistant Colon Cancer (MAC 16) and a human pancreatic cell line (MIAPACA) at 50 mg/kg by oral administration.

Graphical abstract. Left: the 5-hydroxy-5-aryl-pyrrol-2-one structure, where X is H, Cl or F. Right: a chart of percentage change in tumour volume over 22 days, in which the vehicle group rises to about 2,500% while pyrrolones 9 and 10 stay below about 500%.
Graphical abstract published with the paper.

Research behind the publications.

Summaries of every PNB-001 and PNB-028 trial, including Phase 1, Inflammatory Bowel Disease and Type 2 Diabetes, are on the clinical trials page.